

Then, Dr. Sabela C. Mallo from the University of Santiago de Compostela (Spain) and Dr. Byron Creese from the University of Exeter (UK) will talk on methodological issues regarding the MBI-C, the underlying structure of the instrument and the impact of the self and informant ratings in the results of the questionnaire.

Dr. Martin Vyhnalek from the Faculty of Medicine of Prague (Czech Republic) will discuss the MBI profile and severity in a sample of β -amyloid positive individuals with amnesic Mild Cognitive Impairment compared to Cognitively Normal older adults.

Lastly, Dr. Camilla Elefante and Giulio Emilio Brancati from the University of Pisa (Italy) will analyze the relationships and boundaries between MBI and late-life major primary psychiatric disorders in patients who attend to psychogeriatric settings.

Reference

Ismail Z et al. *J. Alzheimers Dis.* 2017; 56(3),929-938

The role of Mild Behavioral Impairment in a future era of Alzheimer's disease modifying treatments

Author: Maurits Johansson, MD, PhD, Lund University.

Early clinical risk markers of neurodegenerative diseases, such as Alzheimer's disease (AD), can be considered fundamental in a new era with novel disease modifying treatments on the horizon. Mild Behavioral Impairment (MBI) is a diagnostic construct defined by the later-life emergence of persistent neuropsychiatric symptoms (e.g. apathy, anxiety, depression, amongst others) displayed by older adults, with the aim to identify individuals at increased risk of future dementia. According to established MBI criteria the syndrome can co-occur with mild cognitive impairment due to a neurodegenerative disease or even precede it, and in fact, MBI is most meaningful when reported in conjunction with cognitive status, as MBI-associated risk is moderated by cognitive status. MBI symptomatology has been reported prevalent among older adults, as well as in patients with early stages of neurodegenerative disease. Symptoms of MBI are further associated with several clinically negative outcomes, such as a reduced quality of life, increased caregiver burden and earlier institutionalization. In support of the MBI construct, several previous reports have demonstrated MBI to be predictive of future cognitive decline, dementia, or AD. The construct is also related to AD biomarkers including beta-amyloid, tau, and cerebral atrophy. Intriguingly, an earlier study indicates that MBI even can precede memory deficits in its association with early tau deposition in cognitively unimpaired elderly with confirmed amyloid-beta pathology, strengthening its position as an early marker of dementing biochemical processes. Despite this growing evidence of being both prevalent and an early prognostic marker, MBI is still only given diminutive consideration in contemporary clinical diagnostic criteria for AD. Perhaps so since the added value of MBI in such criteria has rarely been investigated. Consequently, cognitively unimpaired subjects with positive MBI and AD biomarker status face the risk of not being eligible for a future disease modifying AD treatment since they formally do not fulfill AD diagnostic criteria. Hence, studies exploring the added value of MBI in clinical diagnostic criteria for neurocognitive disorders are prompted.

The assessment of Mild Behavioral Impairment (MBI): Some methodological issues

Authors: Sabela C. Mallo¹, Byron Creese², Eulogio Real-Deus¹, Zahinoor Ismail³, Arturo X Pereiro¹, and Onésimo Juncos-Rabadán¹

(1) University of Santiago de Compostela, Santiago de Compostela, Spain, (2) University of Exeter, UK, (3) University of Calgary, Canada

Objective: The assessment of MBI involves two important issues: 1) to know the underlying structure of the Mild Behavioral Impairment Checklist (MBI-C) a questionnaire designed to evaluate Neuropsychiatric Symptoms (NPS) in pre-dementia states; and 2) to consider self and proxy (i.e., study partner) symptom ratings that may not capture comparable samples. Our objective is to give some answer to these questions: first, to analyze the underlying structure of the MBI-C at baseline and follow-up using Multidimensional Scaling (MDS) and two, to determine how self and proxy ratings and the choice of rating type impact in the results of the MBI-C.